The Library
Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter
Tools
Tools
Tools
(2010) Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. Journal of Clinical Investigation, Vol.120 (No.8). pp. 2842-2857. doi:10.1172/JCI36125 ISSN 0021-9738.
![[img]](https://wrap.warwick.ac.uk/style/images/fileicons/application_pdf.png)
|
PDF
WRAP_Hiller_JCI36125.v2.pdf - Published Version - Requires a PDF viewer. Download (3176Kb) |
Official URL: http://dx.doi.org/10.1172/JCI36125
Abstract
The cytokine TGF-beta acts as a tumor suppressor in normal epithelial cells and during the early stages of tumorigenesis. During malignant progression, cancer cells can switch their response to TGF-beta and use this cytokine as a potent oncogenic factor; however, the mechanistic basis for this is poorly understood. Here we demonstrate that downregulation of disabled homolog 2 (DAB2) gene expression via promoter methylation frequently occurs in human squamous cell carcinomas (SCCs) and acts as an independent predictor of metastasis and poor prognosis. Retrospective microarray analysis in an independent data set indicated that low levels of DAB2 and high levels of TGFB2 expression correlate with poor prognosis. Immunohistochemistry, reexpression, genetic knockout, and RNAi silencing studies demonstrated that downregulation of DAB2 expression modulated the TGF-beta/Smad pathway. Simultaneously, DAB2 down-regulation abrogated TGF-beta tumor suppressor function, while enabling TGF-beta tumor-promoting activities. Downregulation of DAB2 blocked TGF-beta-mediated inhibition of cell proliferation and migration and enabled TGF-beta to promote cell motility, anchorage-independent growth, and tumor growth in vivo. Our data indicate that DAB2 acts as a tumor suppressor by dictating tumor cell TGF-beta responses, identify a biomarker for SCC progression, and suggest a means to stratify patients with advanced SCC who may benefit clinically from anti-TGF-beta therapies.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) | ||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
| Library of Congress Subject Headings (LCSH): | Cytokines, Tumor suppressor proteins, Cocarcinogens, Carcinogenesis | ||||
| Journal or Publication Title: | Journal of Clinical Investigation | ||||
| Publisher: | American Society for Clinical Investigation | ||||
| ISSN: | 0021-9738 | ||||
| Official Date: | 2 August 2010 | ||||
| Dates: |
|
||||
| Volume: | Vol.120 | ||||
| Number: | No.8 | ||||
| Number of Pages: | 16 | ||||
| Page Range: | pp. 2842-2857 | ||||
| DOI: | 10.1172/JCI36125 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Open Access (Creative Commons) | ||||
| Date of first compliant deposit: | 3 December 2015 | ||||
| Date of first compliant Open Access: | 3 December 2015 | ||||
| Funder: | Association for International Cancer Research (AICR), Cancer Research UK (CRUK), Breakthrough Breast Cancer, Institute of Cancer Research: Royal Cancer Hospital, Associazione italiana per la ricerca sul cancro (AIRC), United States. Public Health Service (PHS) | ||||
| Grant number: | GM066257 (PHS) |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
